Adjusted HR for the relationship of SLE with at least 1 serious infection, 3030 patients with SLE and 30,300 general members of Kaiser Permanente (KP).
| Cohort | No. Patients with ≥ 1 Serious Infection | Patient-yrs | Crude Incidence Rate per 100 Patient-yrs | Adjusted HR* | 95% CI |
|---|---|---|---|---|---|
| KP general population | 103 | 27,901 | 0.4 | 1.0 | Ref. |
| SLE with current AM and GC exposure | 39 | 1526 | 2.6 | 6.6 | 4.5–9.5 |
| SLE without current SLE drug use** | 52 | 2090 | 2.5 | 6.0 | 4.2–8.5 |
↵* Adjusted for age (continuous), sex (M/F), and race/ethnicity (5 classes).
↵** For this analysis, we examined risk of infection for patients with SLE during the first period of current use of AM or GC, and during the first period of non-use of any SLE-related drug. Nonusers included only patients who were not current users of any SLE-related drug on the day of the risk set or during the preceding 30 days, including AM, GC, and the following medications: mycophenolate mofetil, azathioprine, methotrexate, cyclophosphamide, cyclosporine, and belimumab. SLE: systemic lupus erythematosus; AM: antimalarials; GC: glucocorticoids.